2018•Current OncologyOpen access

Overcoming Resistance in a BRAF V600e–Mutant Adenocarcinoma of the Lung

Thomas Schmid, Martin Buess

Abstract

We report on a patient with an adenocarcinoma of the lung harbouring a BRAF V600E mutation who benefited from combination therapy with dabrafenib–trametinib after developing resistance to vemurafenib. To our knowledge, our report shows, for the first time, that combination therapy with dabrafenib–trametinib can overcome vemurafenib resistance in a BRAF V600E–mutated adenocarcinoma of the lung.

Open-access reader

About this research paper

What this paper is about

Why it matters

OpenAlex reports 8 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Dabrafenib, Trametinib, Vemurafenib, Medicine, Adenocarcinoma, V600E, Mutation, Cancer research